E
X4 Pharmaceuticals, Inc. XFOR
$1.20 $0.0050.42%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 3/25/2024Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 3/25/2024 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0117 to -$0.0962, operating cash flow declined 33.22% from -$20.83M to -$27.75M, and debt to equity increased from 0.82 to 1.09.
D
Sell 3/21/2024Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 3/21/2024 due to an increase in the total return index and volatility index.
E
Sell 1/23/2024Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 1/23/2024 due to a decline in the total return index and volatility index.
D
Sell 10/23/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 10/23/2023 due to an increase in the volatility index.
E
Sell 10/6/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 10/6/2023 due to a decline in the volatility index and total return index.
D
Sell 9/19/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 9/19/2023 due to an increase in the volatility index.
E
Sell 8/31/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 8/31/2023 due to a decline in the volatility index.
D
Sell 8/14/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 8/14/2023 due to an increase in the solvency index, volatility index and valuation index. The quick ratio increased from 4.83 to 6.39, and debt to equity declined from 0.65 to 0.5.
E
Sell 8/10/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 8/10/2023 due to a decline in the volatility index and total return index.
D
Sell 7/10/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 7/10/2023 due to a major increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.2888 to -$0.1646.
E
Sell 5/8/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 5/8/2023 due to a decline in the volatility index, growth index and valuation index.
D
Sell 4/19/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 4/19/2023 due to an increase in the total return index and volatility index.
E
Sell 3/14/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 03/14/2023.
D
Sell 3/2/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 3/2/2023 due to a decline in the volatility index.
D
Sell 2/13/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from E+ on 2/13/2023 due to an increase in the volatility index.
E
Sell 2/8/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell 2/6/2023Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 2/6/2023 due to an increase in the volatility index.
D
Sell 1/19/2023Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 1/19/2023 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 4.5% from -$18.47M to -$19.31M.
D
Sell 10/17/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 10/17/2022 due to an increase in the volatility index and total return index.
D
Sell 9/30/2022Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 9/30/2022 due to a decline in the volatility index.
D
Sell 9/12/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 9/12/2022 due to an increase in the volatility index and total return index.
D
Sell 8/24/2022Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 8/24/2022 due to a decline in the volatility index.
D
Sell 8/8/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 8/8/2022 due to an increase in the volatility index and growth index. Earnings per share increased from -$0.718 to -$0.5986, operating cash flow increased 8.68% from -$20.23M to -$18.47M, and EBIT increased 5.54% from -$21.78M to -$20.57M.
D
Sell 6/13/2022Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index and total return index.
D
Sell 5/25/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 5/25/2022 due to an increase in the volatility index and total return index.
D
Sell 5/23/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 5/23/2022 due to a large increase in the growth index and volatility index. Earnings per share increased from -$1.2378 to -$0.718.
E
Sell 3/15/2022Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 3/15/2022 due to a decline in the volatility index and total return index.
D
Sell 2/16/2022Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 2/16/2022 due to an increase in the volatility index.
E
Sell 1/31/2022Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 1/31/2022 due to a decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.7403 to -$0.7582, and EBIT declined 0.64% from -$19M to -$19.12M.
D
Sell 8/24/2021Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 8/24/2021 due to a decline in the volatility index and total return index.
D
Sell 8/5/2021Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 8/5/2021 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$1.297 to -$0.7403.
D
Sell 6/14/2021Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 6/14/2021 due to a decline in the volatility index.
D
Sell 5/27/2021Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 5/27/2021 due to an increase in the volatility index.
D
Sell 5/7/2021Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 5/7/2021 due to a noticeable decline in the growth index and volatility index. Earnings per share declined from -$0.9121 to -$1.3, operating cash flow declined 5.37% from -$17.5M to -$18.44M, and EBIT declined 1.59% from -$17.66M to -$17.94M.
D
Sell 2/8/2021Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 2/8/2021 due to an increase in the volatility index and growth index.
D
Sell 9/29/2020Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 9/29/2020 due to a decline in the volatility index and total return index.
D
Sell 9/14/2020Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 9/14/2020 due to an increase in the volatility index.
D
Sell 8/25/2020Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 8/25/2020 due to a decline in the volatility index and total return index.
D
Sell 8/10/2020Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 8/10/2020 due to an increase in the volatility index.
D
Sell 8/5/2020Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to D- from D on 8/5/2020 due to a decline in the volatility index.
D
Sell 6/8/2020Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D from D- on 6/8/2020 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.6581 to -$0.5565.
D
Sell 5/1/2020Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E+ on 5/1/2020 due to an increase in the solvency index and growth index.
E
Sell 3/16/2020Downgrade
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E+ from D- on 3/16/2020 due to a noticeable decline in the growth index, efficiency index and total return index.
D
Sell 12/2/2019Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to D- from E on 12/2/2019 due to an increase in the total return index.
E
Sell 9/3/2019Upgraded
X4 Pharmaceuticals, Inc. (XFOR) was upgraded to E from E- on 9/3/2019 due to a major increase in the solvency index, growth index and valuation index. The quick ratio increased from 1.45 to 6.96, earnings per share increased from -$6.6742 to -$1.0156, and debt to equity declined from 0.66 to 0.28.
E
Sell 6/7/2019None
X4 Pharmaceuticals, Inc. (XFOR) was downgraded to E- from U on 06/07/2019.
Weiss Ratings